Clinical trials: Low Dose
Metastatic Pancreatic Cancer, Pancreatic Cancer
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior…
- Trial name
- PANCRIT®-1 (NCT01956812)
- Testing
- IMMU-107, Gemcitabine
- Where
- 64 sites in United States, Austria and 6 more
- Volunteers
- 334 people
- Sponsor
- Gilead Sciences
HIV Infections
TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients
The purpose of this study is to determine the effectiveness, safety, and tolerability (how well the body stands the drug) of an investigational protease inhibitor (PI) called TMC114 given with low dose ritonavir.
- Trial name
- NCT00071097
- Testing
- TMC114/rtv
- Where
- 39 sites in United States, Argentina
- Volunteers
- 330 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Covid19
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to reduce symptoms, disease severity, and recovery time from COVID-19.
- Trial name
- NCT04604678
- Testing
- Metformin, Naltrexone
- Where
- United States
- Sponsor
- AgelessRx
Low Back Pain
Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain
The objective of this study is to test the idea that the immediate-release (IR) form of tapentadol (CG5503) can be directly converted into an approximately equivalent total daily dose (TDD) of the extended-release (ER) form, and…
- Trial name
- NCT00594516
- Testing
- tapentadol (CG5503) Immediate Release IR, tapentadol (CG5503) Extended Release (ER), tapentadol (CG5503) Immediate Release (IR)
- Volunteers
- 117 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Neutropenia (Low White Blood Cell Count)
A Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Tolerability of Filgrastim Biosimilar and Neupogen Reference Product in Healthy Volunteers
The goal of this clinical trial is to assess the pharmacokinetic similarity of Biofilgragen, a filgrastim biosimilar, compared with EU-authorized Neupogen after single subcutaneous doses in healthy adult volunteers.
- Trial name
- FIL-BIO-IMG (NCT07877467)
- Testing
- Biofilgragen, Neupogen (filgrastim)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BioGeneric Pharma
Diabetes Mellitus, Type 2
Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)
Investigation into patients with type 2 diabetes mellitus not achieving adequate glycemic control while treated with combination of premixed insulin analogue formulations twice daily and metformin will be randomly assigned to…
- Trial name
- S019 (NCT00393705)
- Testing
- Insulin Biphasic Aspart 30/70, insulin lispro LM, insulin lispro MM
- Where
- 9 sites in Croatia, Poland and 3 more
- Volunteers
- 302 people
- Sponsor
- Eli Lilly and Company
Influenza
Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin
There is an obvious need for an affordable and more effective seasonal influenza vaccine. TETRALITE is a novel, inactivated, adjuvanted influenza vaccine combining a low dose of a licensed vaccine with the novel, potent LiteVax…
- Trial name
- TETRALITE-I (NCT05581407)
- Testing
- TETRALITE
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- LiteVax BV
Asthma
Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma
The primary objective of this study was to evaluate the efficacy of fluticasone propionate multidose dry powder inhaler (Fp MDPI) and fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) when…
- Trial name
- NCT02139644
- Testing
- FS MDPI, Fp MDPI, albuterol/salbutamol
- Where
- 140 sites in United States, Canada and 6 more
- Volunteers
- 787 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Vasomotor Symptoms, Hot Flashes
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
The purpose of this study is to determine the lowest effective dose of the study drug for the relief of moderate to severe vasomotor symptoms in postmenopausal women for 12 weeks.
- Trial name
- NCT00446199
- Testing
- 0.5mg DRSP / 0.5mg E2 (BAY86-4891), 0.25mg DRSP / 0.5mg E2 (BAY86-4891), Estradiol (E2 0.3mg)
- Where
- 76 sites in United States
- Volunteers
- 735 people
- Sponsor
- Bayer
Myelodysplastic Syndrome (MDS)
Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia
Phase 1, single-center, open-label, sequential cohort dose escalation study. This is a 3 + 3 design study involving at least 3 subjects in ascending dose cohorts, with subjects participating up to 10 weeks.
- Trial name
- NCT01362036
- Testing
- TXA127
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Tarix Pharmaceuticals
Kidney Transplantation
A Study of CellCept (Mycophenolate Mofetil) Combined With Tacrolimus and Corticosteroids in Kidney Transplant Patients.
This 2 arm study will compare the efficacy and safety of CellCept, combined with low or standard dose tacrolimus plus corticosteroids, in patients with kidney transplants.
- Trial name
- NCT00758602
- Testing
- mycophenolate mofetil, tacrolimus, standard dose, tacrolimus, low dose
- Where
- 6 sites in China
- Volunteers
- 210 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndrome
Dose-Ranging Study of Telintra® Tablets + Revlimid® in Patients With Non-Deletion (5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
This is an open label, multicenter Phase 1 dose escalation study evaluating five doses of ezatiostat in combination with lenalidomide in patients with non-del(5q) low to intermediate 1 risk MDS.
- Trial name
- NCT01062152
- Testing
- Ezatiostat Hydrochloride, Lenalidomide (Revlimid®)
- Where
- 9 sites in United States
- Volunteers
- 19 people
- Sponsor
- Telik
Lung Cancer
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at…
- Trial name
- NCT05987189
- Testing
- Small RNA-based lung cancer assay
- Where
- 11 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Hummingbird Diagnostics
Rheumatoid Arthritis
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
This open-label, single-arm study will assess the use of glucocorticoids (GC) in daily clinical practice and will evaluate the dose reduction of glucocorticoids once low disease activity is achieved in patients with rheumatoid…
- Trial name
- NCT01219933
- Testing
- methylprednisolone, tocilizumab [RoActemra/Actemra]
- Where
- 16 sites in Belgium
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Acute Myeloid Leukemia (AML)
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia…
- Trial name
- NCT03069352
- Testing
- Venetoclax, Cytarabine
- Where
- 109 sites in United States, Argentina and 22 more
- Volunteers
- 211 people
- Sponsor
- AbbVie
Myelodysplastic Syndromes, Cytopenia
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept.
- Trial name
- NCT04419649
- Testing
- Elritercept
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 210 people
- Sponsor
- Takeda
Chronic Kidney Disease, Secondary Hyperparathyroidism
20070360 Incident Dialysis
Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination with Low Dose Vitamin D for the Treatment of Subjects with Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis
- Trial name
- NCT00803712
- Testing
- Cinacalcet, Vitamin D
- Volunteers
- 313 people
- Sponsor
- Amgen
Acute Pain
A Study of the Safety and Efficacy of Combination Therapy With Morphine, Phenylephrine and Sorbitol in Human Subjects
Efficacy and Safety of the combined oral adjuvants phenylephrine and sorbitol on oral low dose morphine analgesia.
- Trial name
- NCT00374881
- Testing
- Morphine, Sorbitol+Phenylephrine, Sorbitol+Phenylephrine+Morphine
- Where
- 2 sites in Israel
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- BioLineRx, Ltd.
Healthy Subjects
A Food Effect Study of Apatinib Mesylate in Healthy Subjects
The primary objective of the study was to assess the effect of high-fat and low-fat meal on the pharmacokinetics of apatinib mesylate in Chinese adult healthy subjects.
- Trial name
- NCT04341090
- Testing
- Apatinib Mesylate
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Asthma
SMILDA - Symbicort®Turbuhaler® Allergan Challenge Study in Allergic Patients With Mild Asthma
To compare the effects of formoterol alone (Oxis® TurbuhalerÒ) and the fixed combination of formoterol and budesonide (Symbicort® TurbuhalerÒ) on airway responsiveness as a marker of inflammation, induced by repeated low-dose…
- Trial name
- NCT00288379
- Testing
- formoterol, budesonide/formoterol
- Where
- Sweden
- Volunteers
- 16 people
- Sponsor
- AstraZeneca